HLE Glascoat (NSE: HLEGLAS) – Outlook (12–24 months)

1. Business position & recent performance

- HLE Glascoat is a specialist in glass‑lined equipment, filtration & drying systems, primarily for pharma and chemical process industries, and is regarded as a leading player with strong share in filtration/drying in India. (forbes.com)

- FY26 consolidated revenue grew ~32% YoY to about ₹1,353 crore, indicating continued strong demand and execution. (icicidirect.com)

- Despite robust top‑line growth, FY26 profit before tax was roughly flat vs FY25, reflecting margin pressure from higher costs/competitive intensity. (icicidirect.com)

- 9M FY26 PAT was up ~21% YoY, but Q3 FY26 standalone PAT fell sharply YoY and QoQ, showing near‑term earnings volatility even within a structurally growing business. (images.moneycontrol.com)

2. Growth drivers – structurally positive

On a 2–3 year view, the business backdrop is broadly favourable:

- Capex cycle in Pharma & Chemicals: Ongoing capacity additions and debottlenecking in specialty chemicals and pharma in India support continued demand for glass‑lined reactors, storage vessels, filters and dryers. HLE Glascoat is directly leveraged to this capex. (screener.in)

- Order book visibility: As of 31 March 2025, the company reported an order book of ~₹575 crore, giving good revenue visibility. Management commentary highlighted a “robust orderbook” entering FY26. (hleglascoat.com)

- Product & geographic diversification: Integration of acquired German player Thaletec strengthens technology and global reach in glass‑lined equipment, helping HLE compete in higher‑end and export markets. (hleglascoat.com)

- Operational scale: FY26 results show the company handling a significantly higher revenue base vs FY24–25 while maintaining profitability, which suggests operating leverage benefits can accrue if margins are managed better. (icicidirect.com)

Taken together, the core business outlook (demand, addressable market, order book) remains structurally positive, assuming no large slowdown in pharma/chem capex.

3. Key risks / monitorables

Investors should track the following closely:

- Margin sustainability: FY26 saw strong revenue growth with relatively flat PBT; Q3 FY26 margins were under pressure. Any further cost inflation (steel, energy, labour) or pricing pressure from competitors can cap earnings growth despite a healthy order book. (icicidirect.com)

- Sector capex cycle: A slowdown in global or domestic chemical/pharma capex would directly affect order inflows for capital equipment like reactors and filter‑dryers.

- Execution of overseas strategy: Benefits from the Thaletec acquisition and any further global expansion need to translate into higher-margin export revenues; integration or Europe‑specific demand issues can dilute returns. (hleglascoat.com)

- Working capital and leverage: Capital‑goods businesses are working‑capital intensive. Management has earlier indicated intent to use cash flows to deleverage and fund growth; slippages here can affect return ratios. (hleglascoat.com)

4. Valuation context (not a recommendation)

- Around 29 June 2026, HLE Glascoat was quoted near ₹375–380 per share. (business-standard.com)

- Using FY26 EPS of about ₹5.55 as per recent result summaries, this implies a trailing P/E in the ~65–70x range at that price level, which is rich versus many traditional industrial capital‑goods names and assumes sustained high growth and margin improvement. (icicidirect.com)

Whether this is reasonable depends on your own view of:

- How fast revenue can grow from the current base,

- How much margin expansion is achievable, and

- Your risk tolerance for cyclical capex‑linked businesses.

Indicative conclusion

- Business outlook: Positive medium‑term demand and order‑book visibility in a niche, high‑entry‑barrier segment; strong positioning in filtration/drying and glass‑lined equipment.

- Earnings trajectory: Likely to grow with sector capex, but with quarter‑to‑quarter volatility and sensitivity to input costs and pricing.

- Stock outlook: Valuation already discounts a fair amount of future growth; any disappointment on margins, order inflows, or sector capex can lead to volatility.

This is an analytical view based on public data and is not investment advice or a buy/sell/hold call. Please evaluate your risk profile, time horizon and consult a SEBI‑registered investment adviser or your broker before taking any exposure.

If you have any further queries, please connect with us on 022-6290-10141 (Timings : 09.00 AM to 05.00 PM) or you can email us on info@cniinfoxchange.com